BURP'S PLACE!

[bUrRpPPP!]

Neurotrope Bioscience to Present at the Noble Financial Capital Markets' 13th Annual Investor Conference

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [e-mail]

SOURCE Neurotrope, Inc.

NEW YORK, Jan. 27, 2017 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRPD), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, announced today that Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, is scheduled to present at the Noble Financial Capital Markets' 13th Annual NobleCON Conference, being held January 29-31, 2017 at the Boca Raton Resort in Boca Raton, Florida.

Details of the presentation are as follows:

Conference:


Noble Financial Capital Markets NobleCON 13

Date:


Monday, January 30, 2017

Time:


1:30 p.m. ET

Location:


Room 1

A video and audio webcast of Neurotrope's presentation will be available at http://noble.mediasite.com/mediasite/Play/c54248f852db4353b8f007b16745782b1d and on the Company's web site at www.neurotropebioscience.com. The webcast and presentation will be archived on Neurotrope's website following the event.

Investors attending the conferences who would like to schedule a 1-on-1 meeting with Dr. Wilke may do so by contacting their Noble representative, or Jeffrey Benison of Neurotrope.

About Neurotrope
Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's disease and other neurodegenerative diseases. The Company's world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer's disease.

The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.

Neurotrope is conducting a Phase 2 trial of bryostatin in the treatment of moderate to severe Alzheimer's disease, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.